What is a GLP-1 Compound? Understanding the Basics and Benefits

Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

"GLP-1 compound" is doing two very different jobs in the same phrase, and confusing them causes real problems. In one sense a compound is simply a chemical entity — semaglutide and tirzepatide are compounds that act on the glucagon-like peptide-1 receptor. In the other sense, "compounded" is a regulatory term describing a preparation made by a licensed pharmacy for an individual patient, which is not the same thing as an FDA-approved drug product. This article separates the two, because the first is about biology and the second is about law.

GLP-1 the Hormone Comes First

Glucagon-like peptide-1 is a hormone your gut releases in response to eating. The Ozempic prescribing information describes it as a physiological hormone with multiple actions on glucose, mediated by GLP-1 receptors. The Wegovy label adds the other half: GLP-1 is a physiological regulator of appetite and caloric intake, and its receptor is present in several brain regions involved in appetite regulation.

Native GLP-1 is broken down within minutes by the enzyme DPP-4, which is why the hormone itself was never a practical medication. Solving that durability problem is what produced the drug class.

The hormone is also not acting alone. Glucose-dependent insulinotropic polypeptide is the other major incretin released after eating, and the fact that a second incretin exists is what made dual-receptor drugs a plausible design rather than a theoretical one.

What Makes a GLP-1 Receptor Agonist

An agonist is a molecule that binds a receptor and switches it on. Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor. The Ozempic label explains the engineering: the principal mechanism of protraction producing semaglutide's long half-life is albumin binding, which reduces renal clearance and protects the molecule from metabolic degradation, and the compound is additionally stabilized against DPP-4.

The practical result is a drug that survives long enough to be dosed once weekly instead of continuously. That is the single design decision that made this class usable outside a hospital.

Half-life also explains why these medications change slowly. The Ozempic label notes an elimination half-life of approximately one week, with semaglutide present in the circulation for about five weeks after the last dose and steady-state exposure reached after four to five weeks of once-weekly administration. Nothing about this class happens quickly in either direction.

What These Compounds Actually Do

Three effects show up consistently in the labeling. Semaglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, meaning the insulin response scales with how high blood glucose actually is. It delays gastric emptying. And it decreases calorie intake through effects the Wegovy label attributes to appetite.

The Wegovy pharmacodynamics section also notes that semaglutide lowers body weight with greater fat mass loss than lean mass loss. That is a description of what was measured, not a promise about body composition for any individual.

Glucose dependence is the safety feature that distinguishes this class from insulin secretagogues that work regardless of blood sugar. It does not eliminate hypoglycemia risk entirely: the labeling notes that concomitant use with insulin or an insulin secretagogue may increase that risk, which is a prescriber-level consideration rather than something to manage on your own.

The Approved Products in This Class

In the United States the semaglutide products are Ozempic injection, Wegovy injection and tablets, and the Rybelsus and Ozempic tablets. Tirzepatide is sold as Mounjaro for glycemic control in type 2 diabetes and as Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea. Each brand has its own application, its own trials and its own labeling.

Brand names are not interchangeable shorthand for a molecule. Mounjaro and Zepbound contain the same active ingredient and are approved for entirely different things, which is why insurers, pharmacies and prescribers treat them as separate products.

The oral landscape has broadened too. Wegovy tablets at 1.5, 4, 9 and 25 mg sit inside the Wegovy label with a 25 mg once-daily maintenance dosage for cardiovascular risk reduction and weight reduction in adults, while Rybelsus and Ozempic tablets serve the type 2 diabetes indications. There is no FDA-approved oral tirzepatide.

Dual Agonists Hit Two Receptors

Tirzepatide is described in its labeling as a glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonist — a single compound with affinity for two incretin receptors rather than one. Its labeling reports an elimination half-life of approximately five days, enabling once-weekly dosing.

In the 72-week SURMOUNT-1 trial of 2,539 adults with obesity or overweight and without diabetes, mean weight change was −15.0%, −19.5% and −20.9% across the three doses studied versus −3.1% with placebo. Different molecule, different receptor profile, different trial program — which is why cross-trial comparisons should be read carefully.

Direct comparisons are rarer than the internet suggests. Trials differ in duration, in whether participants had diabetes, in the intensity of the lifestyle program, and in how missing data were handled. Two numbers from two different studies are not a head-to-head result, and treating them as one is the most common analytical error in this space.

What "Compounded" Means at a Pharmacy

Compounding is the preparation of a medication by a licensed pharmacy pursuant to a prescription for an individual patient. Compounded preparations are not FDA-approved, and the agency does not review them for safety, effectiveness or quality before they reach a patient. Section 503A of the Federal Food, Drug, and Cosmetic Act governs state-licensed pharmacies and physicians doing this work.

The regulatory picture shifted sharply in 2025. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then set dates after which compounders could no longer produce preparations that are essentially copies of the approved products — February 18, 2025 for 503A pharmacies on tirzepatide and April 22, 2025 for 503A pharmacies on semaglutide.

The phrase "essentially a copy" is the hinge. Compounding did not become illegal; producing duplicates of commercially available approved products under a shortage rationale did. Compounding that reflects a documented clinical need for an individual patient remains within the 503A framework, which is why licensed compounding continues after those dates.

Telling the Two Apart

An approved product has an FDA-reviewed label, a national drug code, and a manufacturer accountable for every lot. A compounded preparation has a pharmacy, a prescription and a patient name. Neither of those is inherently a scandal — compounding is a long-standing and legitimate part of pharmacy practice — but they are not the same category and should never be described as if they were.

The failure mode to watch is the third thing: material sold online with no prescriber and no pharmacy, often labeled for research use. The FDA has announced its intent to restrict GLP-1 active pharmaceutical ingredients destined for non-FDA-approved compounded drugs and to act against marketing that presents compounded products as equivalent to approved ones.

A practical test: can you name the prescriber, name the pharmacy, and see the state license? If any of those three answers is missing, you are not looking at compounding in the regulated sense of the word, whatever the website calls itself.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does "GLP-1 compound" mean a compounded medication?

Not necessarily, and that ambiguity causes confusion. In chemistry, a compound is simply a molecule, so semaglutide and tirzepatide are GLP-1 compounds in that sense. In pharmacy regulation, compounded means a preparation made by a licensed pharmacy pursuant to a prescription for an individual patient, which is not an FDA-approved product. When you see the phrase, check which meaning is intended before drawing any conclusion about approval status.

How does a GLP-1 receptor agonist work?

It binds and activates the GLP-1 receptor, the same target as the natural hormone. According to the prescribing information, semaglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, delays gastric emptying, and decreases calorie intake through effects on appetite. GLP-1 receptors are present in several brain regions involved in appetite regulation, which is why the class affects hunger as well as blood sugar.

Why are these medications dosed once weekly?

Because they are engineered to resist rapid breakdown. Native GLP-1 is degraded within minutes by the DPP-4 enzyme. The Ozempic label explains that semaglutide binds albumin, which decreases renal clearance and protects it from metabolic degradation, and that it is stabilized against DPP-4. Tirzepatide labeling reports an elimination half-life of approximately five days, which is what enables once-weekly administration.

What is the difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 analogue that activates one receptor. Tirzepatide is described in its labeling as a glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonist, meaning it acts at two incretin receptors. They were studied in separate trial programs, carry separate labels, and are sold under different brand names. Which one is appropriate for a given person is a clinical decision made by a prescriber.

Are compounded GLP-1 medications FDA approved?

No. Compounded preparations are not FDA-approved products, and the agency does not review them for safety, effectiveness or quality before marketing. They are prepared by licensed pharmacies pursuant to individual prescriptions. Following the resolution of the semaglutide and tirzepatide shortages, the FDA set 2025 deadlines after which compounders could no longer produce preparations that are essentially copies of the approved drugs.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.